VOYAGER THERAPEUTICS INC (VYGR) Fundamental Analysis & Valuation

NASDAQ:VYGR • US92915B1061

Current stock price

4.23 USD
+0.1 (+2.42%)
At close:
4.23 USD
0 (0%)
After Hours:

This VYGR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. VYGR Profitability Analysis

1.1 Basic Checks

  • In the past year VYGR has reported negative net income.
  • In the past year VYGR has reported a negative cash flow from operations.
  • In the past 5 years VYGR reported 4 times negative net income.
  • In the past 5 years VYGR reported 4 times negative operating cash flow.
VYGR Yearly Net Income VS EBIT VS OCF VS FCFVYGR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M -100M

1.2 Ratios

  • VYGR's Return On Assets of -47.46% is in line compared to the rest of the industry. VYGR outperforms 47.87% of its industry peers.
  • VYGR has a Return On Equity (-61.06%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -47.46%
ROE -61.06%
ROIC N/A
ROA(3y)-8.77%
ROA(5y)-18.43%
ROE(3y)-8.92%
ROE(5y)-36.05%
ROIC(3y)N/A
ROIC(5y)N/A
VYGR Yearly ROA, ROE, ROICVYGR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

1.3 Margins

  • VYGR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VYGR Yearly Profit, Operating, Gross MarginsVYGR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. VYGR Health Analysis

2.1 Basic Checks

  • VYGR does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, VYGR has more shares outstanding
  • VYGR has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for VYGR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VYGR Yearly Shares OutstandingVYGR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
VYGR Yearly Total Debt VS Total AssetsVYGR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • Based on the Altman-Z score of -0.57, we must say that VYGR is in the distress zone and has some risk of bankruptcy.
  • VYGR has a Altman-Z score (-0.57) which is comparable to the rest of the industry.
  • VYGR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.57
ROIC/WACCN/A
WACC9.46%
VYGR Yearly LT Debt VS Equity VS FCFVYGR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

  • A Current Ratio of 7.64 indicates that VYGR has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 7.64, VYGR is in the better half of the industry, outperforming 69.57% of the companies in the same industry.
  • VYGR has a Quick Ratio of 7.64. This indicates that VYGR is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 7.64, VYGR is in the better half of the industry, outperforming 69.96% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.64
Quick Ratio 7.64
VYGR Yearly Current Assets VS Current LiabilitesVYGR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. VYGR Growth Analysis

3.1 Past

  • VYGR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -79.65%.
  • Looking at the last year, VYGR shows a very negative growth in Revenue. The Revenue has decreased by -49.53% in the last year.
  • VYGR shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -25.08% yearly.
EPS 1Y (TTM)-79.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.03%
Revenue 1Y (TTM)-49.53%
Revenue growth 3Y-0.43%
Revenue growth 5Y-25.08%
Sales Q2Q%144.28%

3.2 Future

  • Based on estimates for the next years, VYGR will show a small growth in Earnings Per Share. The EPS will grow by 3.35% on average per year.
  • VYGR is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.27% yearly.
EPS Next Y8.97%
EPS Next 2Y6.56%
EPS Next 3Y6.2%
EPS Next 5Y3.35%
Revenue Next Year49.31%
Revenue Next 2Y26.94%
Revenue Next 3Y28.51%
Revenue Next 5Y13.27%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VYGR Yearly Revenue VS EstimatesVYGR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M
VYGR Yearly EPS VS EstimatesVYGR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -5 -10

More info and screens

Find the best growth stocksShow best growing peers

0

4. VYGR Valuation Analysis

4.1 Price/Earnings Ratio

  • VYGR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VYGR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VYGR Price Earnings VS Forward Price EarningsVYGR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VYGR Per share dataVYGR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.56%
EPS Next 3Y6.2%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VYGR Dividend Analysis

5.1 Amount

  • VYGR does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VYGR Fundamentals: All Metrics, Ratios and Statistics

VOYAGER THERAPEUTICS INC

NASDAQ:VYGR (4/20/2026, 4:30:02 PM)

After market: 4.23 0 (0%)

4.23

+0.1 (+2.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-09
Earnings (Next)05-12
Inst Owners60.95%
Inst Owner Change0.06%
Ins Owners1.01%
Ins Owner Change1.67%
Market Cap252.11M
Revenue(TTM)40.37M
Net Income(TTM)-119.72M
Analysts87.78
Price Target17.17 (305.91%)
Short Float %6.53%
Short Ratio4.5
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.56%
Min EPS beat(2)11.46%
Max EPS beat(2)11.66%
EPS beat(4)2
Avg EPS beat(4)0.27%
Min EPS beat(4)-15.73%
Max EPS beat(4)11.66%
EPS beat(8)5
Avg EPS beat(8)15.12%
EPS beat(12)9
Avg EPS beat(12)77.64%
EPS beat(16)10
Avg EPS beat(16)65.48%
Revenue beat(2)2
Avg Revenue beat(2)55.05%
Min Revenue beat(2)43.35%
Max Revenue beat(2)66.75%
Revenue beat(4)2
Avg Revenue beat(4)2.09%
Min Revenue beat(4)-53.19%
Max Revenue beat(4)66.75%
Revenue beat(8)5
Avg Revenue beat(8)44.79%
Revenue beat(12)9
Avg Revenue beat(12)99.91%
Revenue beat(16)10
Avg Revenue beat(16)75.12%
PT rev (1m)12.22%
PT rev (3m)12.22%
EPS NQ rev (1m)0.98%
EPS NQ rev (3m)-8.98%
EPS NY rev (1m)-13.13%
EPS NY rev (3m)-13.13%
Revenue NQ rev (1m)-3.58%
Revenue NQ rev (3m)-12.88%
Revenue NY rev (1m)0.63%
Revenue NY rev (3m)-13.07%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.24
P/FCF N/A
P/OCF N/A
P/B 1.29
P/tB 1.29
EV/EBITDA N/A
EPS(TTM)-2.03
EYN/A
EPS(NY)-1.85
Fwd EYN/A
FCF(TTM)-2.27
FCFYN/A
OCF(TTM)-2.22
OCFYN/A
SpS0.68
BVpS3.29
TBVpS3.29
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -47.46%
ROE -61.06%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-8.77%
ROA(5y)-18.43%
ROE(3y)-8.92%
ROE(5y)-36.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 63.94%
Cap/Sales 6.43%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.64
Quick Ratio 7.64
Altman-Z -0.57
F-Score2
WACC9.46%
ROIC/WACCN/A
Cap/Depr(3y)70.56%
Cap/Depr(5y)56.61%
Cap/Sales(3y)4.04%
Cap/Sales(5y)4.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-79.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.03%
EPS Next Y8.97%
EPS Next 2Y6.56%
EPS Next 3Y6.2%
EPS Next 5Y3.35%
Revenue 1Y (TTM)-49.53%
Revenue growth 3Y-0.43%
Revenue growth 5Y-25.08%
Sales Q2Q%144.28%
Revenue Next Year49.31%
Revenue Next 2Y26.94%
Revenue Next 3Y28.51%
Revenue Next 5Y13.27%
EBIT growth 1Y-63.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.02%
EBIT Next 3Y0.41%
EBIT Next 5Y0.17%
FCF growth 1Y-617.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-765.23%
OCF growth 3YN/A
OCF growth 5YN/A

VOYAGER THERAPEUTICS INC / VYGR Fundamental Analysis FAQ

What is the fundamental rating for VYGR stock?

ChartMill assigns a fundamental rating of 3 / 10 to VYGR.


What is the valuation status of VOYAGER THERAPEUTICS INC (VYGR) stock?

ChartMill assigns a valuation rating of 0 / 10 to VOYAGER THERAPEUTICS INC (VYGR). This can be considered as Overvalued.


How profitable is VOYAGER THERAPEUTICS INC (VYGR) stock?

VOYAGER THERAPEUTICS INC (VYGR) has a profitability rating of 1 / 10.


What is the earnings growth outlook for VOYAGER THERAPEUTICS INC?

The Earnings per Share (EPS) of VOYAGER THERAPEUTICS INC (VYGR) is expected to grow by 8.97% in the next year.